Current perspectives on pharmacotherapy of Alzheimer's disease
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Alzheimer's disease (AD) is a daunting public health threat that has prompted the scientific community's ongoing efforts to decipher the underlying disease mechanism, and thereafter, target this therapeutically. Although basic research in AD has made remarkable progress over the past two decades, currently available drugs can only improve cognitive symptoms temporarily; no treatment can reverse, stop, or even slow this inexorable neurodegenerative process. Numerous disease-modifying strategies targeting the production and clearance of Aβ, as well as modulation of abnormal aggregation of tau filaments, are currently in clinical trials . AREAS COVERED: this review provides an overview of a wide array of therapeutic approaches under investigation, and the perspectives developed in the last 10 years. EXPERT OPINION: While it is not possible to predict the success of any individual program, one or more are likely to prove effective. Indeed, it seems reasonable to predict that in the not-too-distant future, a synergistic combination of agents will have the capacity to alter the neurodegenerative cascade and reduce the global impact of this devastating disease. The scientific community must acknowledge that Alzheimer's disease is a complex multifactorial disorder, and thus a single target or pathogenic pathway is unlikely to be identified. The major aim should be to design ligands with pluripotent pharmacological activities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intracellular amyloid-β in Alzheimer's disease
LaFerla, F. M., Green, K. N., & Oddo, S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2168 · Cited by 1,942
Aβ Oligomers – a decade of discovery
Walsh, D. M., & Selkoe, D. J. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04426.x · Cited by 1,938 · cited 1×
“Thus the role of Ab, whether it is a culprit or a protector, will further our understanding of the disease pathology and thus influence the design of new therapeutic approaches [27].”
BackgroundHolmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R. W., Bullock, R., Love, S., Neal, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61075-2 · Cited by 1,416 · cited 1×
“Although immunization with Ab(42) resulted in clearance of amyloid plaques in patients with Alzheimer’s disease, this clearance did not prevent progressive neurodegeneration [44].”
BackgroundTariot, P. N., Farlow, M. R., Grossberg, G. T., Graham, S. M., McDonald, S., Gergel, I., & for the Memantine Study Group (2004) · JAMA · doi:10.1001/jama.291.3.317 · Cited by 1,403
Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
Gilman, S., Koller, M., Black, R. S., Jenkins, L., Griffith, S. G., Fox, N. C., Eisner, L., Kirby, L., Rovira, M. B., Forette, F., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000159740.16984.3c · Cited by 1,329 · cited 1×
“trend: patients with AD who developed an antibody response improved over a 12-month period in some neuropsychological tests [42].”
BackgroundLindsay, J. (2002) · American Journal of Epidemiology · doi:10.1093/aje/kwf074 · Cited by 1,261 · cited 1×
“2 Resveratrol Resveratrol, a polyphenolic phytoalexin found in grapes, red wine and berries, has been reported to possess a wide range of biological and pharmacological activities [72].”
BackgroundLuo, Y., Bolon, B., Kahn, S., Bennett, B. D., Babu-Khan, S., Denis, P., Fan, W., Kha, H., Zhang, J., Gong, Y., et al. (2001) · Nature Neuroscience · doi:10.1038/85059 · Cited by 1,001
Freund-Levi, Y., Eriksdotter-Jönhagen, M., Cederholm, T., Basun, H., Faxén-Irving, G., Garlind, A., Vedin, I., Vessby, B., Wahlund, L.-O., & Palmblad, J. (2006) · Archives of Neurology · doi:10.1001/archneur.63.10.1402 · Cited by 751
Lannfelt, L., Blennow, K., Zetterberg, H., Batsman, S., Ames, D., Harrison, J., Masters, C. L., Targum, S., Bush, A. I., Murdoch, R., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70167-4 · Cited by 725
Risner, M. E., Saunders, A. M., Altman, J. F. B., Ormandy, G. C., Craft, S., Foley, I. M., Zvartau-Hind, M. E., Hosford, D. A., Roses, A. D., & for the Rosiglitazone in Alzheimer's Disease Study Group (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500369 · Cited by 686
Targeting acetylcholinesterase and butyrylcholinesterase in dementia
Lane, R. M., Potkin, S. G., & Enz, A. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705005833 · Cited by 654
NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo
Eriksen, J. L., Sagi, S. A., Smith, T. E., Weggen, S., Das, P., McLendon, D. C., Ozols, V. V., Jessing, K. W., Zavitz, K. H., Koo, E. H., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18162 · Cited by 634 · cited 1×
“Tarenflurbil, the enantiomer of the NSAID flurbiprofen, modulates the activity of g-secretase, thereby reducing Ab [33].”
BackgroundBaum, L., & Ng, A. (2004) · Journal of Alzheimer s Disease · doi:10.3233/jad-2004-6403 · Cited by 483
Rezai-Zadeh, K., Arendash, G. W., Hou, H., Fernandez, F., Jensen, M., Runfeldt, M., Shytle, R. D., & Tan, J. (2008) · Brain Research · doi:10.1016/j.brainres.2008.02.107 · Cited by 459
Deane, R., Wu, Z., & Zlokovic, B. V. (2004) · Stroke · doi:10.1161/01.str.0000143452.85382.d1 · Cited by 392
Sastre, M., Dewachter, I., Rossner, S., Bogdanovic, N., Rosen, E., Borghgraef, P., Evert, B. O., Dumitrescu-Ozimek, L., Thal, D. R., Landreth, G., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503839103 · Cited by 373
Methylene Blue Delays Cellular Senescence and Enhances Key Mitochondrial Biochemical Pathways
Atamna, H., Nguyen, A., Schultz, C., Boyle, K., Newberry, J., Kato, H., & Ames, B. N. (2008) · The FASEB Journal · doi:10.1096/fj.07-9610com · Cited by 272
A comparative study in rodents of standardized extracts of Bacopa monniera and Ginkgo biloba
Das, A., Shanker, G., Nath, C., Pal, R., Singh, S., & Singh, H. K. (2002) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(02)00940-1 · Cited by 264
Ishrat, T., Hoda, M. N., Khan, M. B., Yousuf, S., Ahmad, M., Khan, M. M., Ahmad, A., & Islam, F. (2009) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2009.02.002 · Cited by 230 · cited 1×
“Curcumin also activates glutathione S-transferase and partially restores glutathione content in the brain [65,66].”
BackgroundCandelario-Jalil, E., de Oliveira, A. C. P., Gräf, S., Bhatia, H. S., Hüll, M., Muñoz, E., & Fiebich, B. L. (2007) · Journal of Neuroinflammation · doi:10.1186/1742-2094-4-25 · Cited by 223
Combination Therapy in Alzheimer???s Disease: A Review of Current Evidence
Schmitt, B., Bernhardt, T., Moeller, H.-J., Heuser, I., & Fr??lich, L. (2004) · CNS Drugs · doi:10.2165/00023210-200418130-00001 · Cited by 182
Trombino, S., Serini, S., Di Nicuolo, F., Celleno, L., Andò, S., Picci, N., Calviello, G., & Palozza, P. (2004) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf0303924 · Cited by 159 · cited 1×
“In a recent in vitro study, Trombino and colleagues evaluated the ability of ferulic acid to inhibit lipid peroxidation in rat liver microsomal membranes and ROS production in fibroblasts [101].”
BackgroundPreliminary studies of a novel bifunctional metal chelator targeting Alzheimer's amyloidogenesis
Dedeoglu, A., Cormier, K., Payton, S., Tseitlin, K. A., Kremsky, J. N., Lai, L., Li, X., Moir, R. D., Tanzi, R. E., Bush, A. I., et al. (2004) · Experimental Gerontology · doi:10.1016/j.exger.2004.08.016 · Cited by 141 · cited 1×
“Several chelators of Zn/Cu have been shown to inhibit Ab aggregation in vitro and in animal studies [55].”
BackgroundLeroy, K., Ando, K., Héraud, C., Yilmaz, Z., Authelet, M., Boeynaems, J.-M., Buée, L., De Decker, R., & Brion, J.-P. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1276 · Cited by 103 · cited 1×
“One is inhibiting tau kinases [111]; others involve supporting microtubule assembly [112].”
BackgroundTreatment of Alzheimers Disease: Symptomatic and Disease-Modifying Approaches
Galimberti, D., & Scarpini, E. (2010) · Current Aging Science · doi:10.2174/1874609811003010046 · Cited by 51 · cited 1×
“Prospective studies of rofecoxib, naproxen, diclofenac, celecoxib, dapsone, hydroxychloroquine and nimesulide failed to slow progression of cognitive decline in patients with mild-to-moderate AD [108].”
Background
Cited by
Natural AChE Inhibitors from Plants and their Contribution to Alzheimer’s Disease Therapy
Murray, A., Faraoni, M., Castro, M., Alza, N., & Cavallaro, V. (2013) · Current Neuropharmacology · doi:10.2174/1570159x11311040004 · Cited by 341
Oxidized cholesterol as the driving force behind the development of Alzheimer’s disease
Gamba, P., Testa, G., Gargiulo, S., Staurenghi, E., Poli, G., & Leonarduzzi, G. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00119 · Cited by 180
Misra, S., Chopra, K., Sinha, V. R., & Medhi, B. (2016) · Drug Delivery · doi:10.3109/10717544.2015.1089956 · Cited by 136
“Acetylcholinesterase (AChE) inhibitors are currently the only approved class of drugs according to US food and drug administration for the symptomatic treatment of AD (Chopra et al., 2011b).”
BackgroundSelf-citationArya, A., Chahal, R., Rao, R., Rahman, M. H., Kaushik, D., Akhtar, M. F., Saleem, A., Khalifa, S. M. A., El-Seedi, H. R., Kamel, M., et al. (2021) · Biomolecules · doi:10.3390/biom11030350 · Cited by 111
Georgieva, D., Nikolova, D., Vassileva, E., & Kostova, B. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030829 · Cited by 60
Metadata
- Authors
- Chopra, K., Misra, S., & Kuhad, A.
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa Healthcare
- Published
- 2011-01-11
- Volume
- 12
- Issue
- 3
- Pages
- 335-350
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W1998890058
- Cited by
- 74
- References
- 25
- FWCI
- 3.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.